Oral Aleniglipron Reduced Weight at 36 Weeks - Top-Institutions - MDSpire

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

  • By

  • Kathryn Wighton

  • July 16, 2026

  • 6 min

Share

Top Institutions in Internal Medicine

Brief introduction explaining scope and methodology.

  • #1

    UT Southwestern Medical Center
    UT Southwestern Medical Center

    Dallas, Texas

    Key Differentiators

    • Endocrinology
    • Obesity Research

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Endocrinology

  • #3

    Yale School of Medicine
    Yale School of Medicine

    New Haven, Connecticut

    Key Differentiators

    • Endocrinology
    • Diabetes Research

  • #4

    University of Pennsylvania
    University of Pennsylvania

    Philadelphia, Pennsylvania

    Key Differentiators

    • Endocrinology

  • #5

    University of North Carolina School of Medicine
    University of North Carolina School of Medicine

    Chapel Hill, North Carolina

    Key Differentiators

    • Endocrinology

Original Source(s)

Oral Aleniglipron Reduced Weight at 36 Weeks

  • by Kathryn Wighton

  • July 16, 2026

Related Content

Echo AI: From Innovation to Adoption

Experts examined the evidence, practical applications, and barriers shaping AI integration in echocardiography.

Triglycerides Linked to Psoriasis Risk

Genetically predicted triglyceride levels were associated with higher odds of psoriasis, while genetically predicted total fatty acid levels were not, in a two-sample Mendelian randomization analysis.

Serostatus May Modify RA Activity–CV Link

Combined rheumatoid factor and anticitrullinated protein antibody status appeared to modify the association between baseline rheumatoid arthritis disease activity and subsequent cardiovascular events in an international observational cohort.